Article Commentary: Who's in Favor of Translational Cell Therapy for Stroke: STEPS Forward Please?

Abstract

A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.